Boehringer Ingelheim and Eli Lilly (NYSE:LLY) touted post-hoc analyses today showing that Jardiance reduced the risk of cardiovascular death in people with Type II diabetes and established cardiovascular disease, independent of blood sugar control at the start of the study. The companies also reported a reduced risk in cardiovascular death when Jardiance was added to first […]
Pharmaceuticals
Ascensia Diabetes Care partners for mobile insulin management app
Ascensia Diabetes Care and Quattro Folia said today that the companies are partnering to combine Ascensia’s Contour Next One blood glucose monitoring system and Quattro Folia’s Balansio mobile insulin management app. According to the deal, the Contour Next One meter will connect via Bluetooth to the Balansio mobile app and deliver blood glucose readings to […]
Study: Sanofi’s diabetes drug brings earlier blood sugar control than insulin glargine
A post-hoc analysis of two late-stage trials of Sanofi‘s (NYSE:SNY) Soliqua insulin glargine and lixisenatide injection showed that it provides blood sugar control earlier and in more adults than just insulin glargine, the company reported. The analysis was presented today at the European Association for the Study of Diabetes in Portugal. Researchers reviewed data from […]
Study: Children with asthma more likely to be prescribed unnecessary antibiotics
Kids with asthma are more likely to be prescribed antibiotics, despite the fact that they don’t need them more than kids without asthma, according to a study that is slated to be presented at the European Respiratory Society International Congress. Researchers from Erasmus University in the Netherlands pointed out that it’s possible that asthma symptoms […]
Allergan alleges Imprimis makes, sells and promotes unapproved drugs – and Imprimis fires back
Last week, Allergan (NYSE:AGN) said that it filed lawsuits against Imprimis Pharmaceuticals (NSDQ:IMMY), Prescriber’s Choice and Sincerus Florida, claiming that the companies manufacture, sell and promote unapproved new drugs. The pharmaceutical giant filed suit in the U.S. District Court for the Central District of California. Today, Imprimis fired back at Allergan, denying the allegations and saying that […]
Regeneron, Sanofi tout topline Ph3 data for injectable asthma drug
Sanofi (NYSE:SNY) and Regeneron (NSDQ:REGN) touted data today from the pivotal Phase III trial of dupilumab in a group of patients with uncontrolled, persistent asthma. The drug is already approved for adults with certain forms of eczema. The two companies said they plan to seek FDA approval of dupilumab in asthma by the end of the year. […]
Medtronic recalls insulin infusion sets
Medtronic (NYSE:MDT) said today that it’s recalling some of the infusion sets used with its insulin pumps due to problems with a discontinued component. The Fridley, Minn.-based medical device titan said the problem involves a vent membrane that’s susceptible to blockage during priming and fill-tubing. No pumps or glucose sensors are affected by the recall, Medtronic […]
Replicel prototypes its next-gen dermal injector
RepliCel Life Sciences (OTC:REPCF) said yesterday that it has developed prototypes of its RCI-02 motorized injection device designed with programmable depth and volume, as well as interchangeable needle head configurations. The injector was built to deliver an array of substances, including dermal fillers, drugs, cells or biologics intradermally, subcutaneously or intramuscularly. The company said it hopes […]
Lyndra lands $105m deal with Allergan for once-weekly Alzheimer’s drugs
Boston-based startup Lyndra said today that it is partnering with pharma giant Allergan (NYSE:AGN) to develop orally administered, once-weekly products for the treatment of Alzheimer’s disease. The collaboration will combine Allergan’s proprietary Alzheimer’s drugs with Lyndra’s sustained-release technology, which is designed to temporarily reside in the stomach for up to one week while delivering a drug. […]
Japan approves Medtronic’s In.Pact Admiral drug-coated balloon
Medtronic (NYSE:MDT) said today that its In.Pact Admiral drug-coated balloon won approval from the Japanese Ministry of Health, Labour and Welfare for the treatment of peripheral artery disease in the upper leg. Before the medtech giant can begin commercialization of its drug-device combination product, it must gain reimbursement from the Japanese regulatory body, Medtronic said. “The […]